Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
JAMA Network Open|January 10, 2022
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United KingdomChanjira Satukijchai, Romina Mariano, Silvia Messina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccinationSafiya A Zaloum, Callum H Wood, Pooja Tank, et al.
Annals of Neurology|October 23, 2021
COVID-19 Vaccine Response in People with Multiple SclerosisEmma C Tallantyre, Nicola Vickaryous, Valerie Anderson, et al.
Annals of Neurology|July 3, 2023
Do Early Relapses Predict the Risk of Long-Term Relapsing Disease in an Adult and Paediatric Cohort with MOGAD?Bo Chen, Enrique Gomez-Figueroa, Vyanka Redenbaugh, et al.
European Journal of Human Genetics : EJHG|March 19, 2009
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factorMaria Ban, An Goris, Aslaug R Lorentzen, et al.
European Journal of Neurology|April 3, 2024
Real-world persistence of multiple sclerosis disease-modifying therapiesEmma C Tallantyre, Ruth Dobson, Joseph L J Froud, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Nature Genetics|October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Pageof 7